Analysis of the clinical efficacy of percutaneous transluminal angioplasty in treating dysfunction of autogenous arteriovenous fistula
10.3969/j.issn.1002-1671.2025.04.026
- VernacularTitle:经皮腔内血管成形术治疗自体动静脉内瘘失功的临床疗效分析
- Author:
Jingcun SU
1
;
Haiyang WANG
1
;
Junbo LI
1
;
Huawen XIA
1
Author Information
1. 邯郸市第一医院介入血管外科,河北 邯郸 056000
- Publication Type:Journal Article
- Keywords:
autogenous arteriovenous fistula;
percutaneous transluminal angioplasty;
influencing factors
- From:
Journal of Practical Radiology
2025;41(4):656-659
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the efficacy of percutaneous transluminal angioplasty(PTA)in the treatment of dysfunction of autogenous arteriovenous fistula(AVF),and to analyze the factors influencing 12-month patency.Methods The data from maintenance hemodialysis patients who underwent PTA for AVF stenosis were collected.The technical success rate,clinical success rate,complications,and short-to medium-term AVF patency were evaluated.Univariate analysis and binary logistic regression were used to identify predictors of 12-month post-procedural patency.Results A total of 70 patients were included in this study.The technical and clinical success rates were 94.29%and 95.71%,respectively.The 3-,6-,and 12-month post-procedural patency rates of AVF were 97.1%,75.7%,and 61.4%,respectively.Independent protective factors for 12-month AVF patency included age＜60 years[odds ratio(OR)=0.277,95%confidence interval(CI)0.097-0.792]and statin use(OR=0.299,95%CI 0.101-0.887).Independent risk factors included diabetes mellitus(OR=5.167,95%CI 1.824-14.64),AVF usage≥1 year(OR=2.885,95%CI 1.061-7.840),and non-use of aspirin(OR=2.782,95%CI 1.016-7.615).Conclusion PTA is a safe and effective treatment for AVF stenosis,though long-term patency rates require further improvement.
